FDA Inspection 1134720 — Zhejiang Guobang Pharmaceutical Co., Ltd
The FDA completed an inspection of Zhejiang Guobang Pharmaceutical Co., Ltd on January 10, 2020 in Shaoxing. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- January 10, 2020
- Fiscal Year
- 2020
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Shaoxing (China)
Additional Details
Mutual Recognition Agreement (MRA)